Trials / Active Not Recruiting
Active Not RecruitingNCT02810743
Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer
Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer Patients With Personalized Therapy (SUBITO) - an International Randomized Phase III Trial
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 174 (estimated)
- Sponsor
- The Netherlands Cancer Institute · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Investigator-initiated, international, multicentre, randomized, open-label, (neo)adjuvant phase III study in target population (stage III, HER2-negative, BRCA1-like breast cancer patients) comparing optimized standard-dose chemotherapy with intensified, alkylating chemotherapy with stem cell rescue.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ddAC-CP-Olaparib | ddAC-CP-Olaparib |
| DRUG | ddAC-mini CTC | ddAC - mini CTC |
Timeline
- Start date
- 2017-01-25
- Primary completion
- 2024-07-18
- Completion
- 2033-12-01
- First posted
- 2016-06-23
- Last updated
- 2025-11-26
Locations
11 sites across 2 countries: France, Netherlands
Source: ClinicalTrials.gov record NCT02810743. Inclusion in this directory is not an endorsement.